Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

The studies - both conducted in patient samples and animal models - found that inhibiting a protein called RSK1 reduces inflammation and stops the progression of blood cancers called myeloproliferative neoplasms (MPNs) as well as an aggressive form of acute myeloid leukemia (AML).

A new study in Nature by last year's Nobel Laureate in Chemistry reveals a possible game-changer in snakebite treatment. Researchers have created new proteins that neutralise lethal toxins found in snake venom, potentially offering a safer and more effective alternative to traditional antivenoms.

According to the WHO, venomous snakebites affect between 1,8 and 2,7 million people each year,

With antibiotic resistance a growing problem, University of Virginia School of Medicine researchers have developed cutting-edge computer models that could give the disease-fighting drugs a laser-like precision to target only specific bacteria in specific parts of the body.

As it stands, antibiotics kill bacteria indiscriminately.

Scientists at the University of Stuttgart have succeeded in controlling the structure and function of biological membranes with the help of "DNA origami". The system they developed may facilitate the transportation of large therapeutic loads into cells. This opens up a new way for the targeted administration of medication and other therapeutic interventions. Thus, a very valuable instrument can be added to the toolbox of synthetic biology.

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust immune system CAR-Ts (chimeric antigen receptor-T cells) to fight cancer. This finding may have a significant impact on improving the production of CAR-T cells for clinical use.

Researchers from POSTECH and Kyungpook National University have developed a novel inhalable therapeutic delivery system for lung cancer, leveraging mucoadhesive protein nanoparticles inspired by the adhesive properties of marine mussels. This effort was spearheaded by Professor Hyung Joon Cha (Department of Chemical Engineering and Graduate School of Convergence Science and Technology with a specialization in Medical Science) and Dr. Yeonsu Jeong (Department of Chemical Engineering) at POSTECH, in collaboration with

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular dystrophy with the help of gene-editing. Preclinical research led by the Spuler Lab published in Nature Communications now paves the way for first-in-human clinical trials.

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and Charité - Universitätsmedizin Berlin, have developed a promising gene-editing approach intended to restore the function of a protein that is essential to repair and regrow muscle in patients with muscular dystrophy diseases.